Biodexa Pharmaceuticals (BDRX)
1.45
0.05 (3.57%)
At close: Apr 23, 2025, 3:59 PM
1.31
-9.34%
Pre-market: Apr 24, 2025, 04:27 AM EDT
3.57% (1D)
| Bid | 1.27 |
| Market Cap | 2.42K |
| Revenue (ttm) | 83K |
| Net Income (ttm) | -6.82M |
| EPS (ttm) | -13.23 |
| PE Ratio (ttm) | -0.11 |
| Forward PE | n/a |
| Analyst | n/a |
| Ask | 1.44 |
| Volume | 104,871 |
| Avg. Volume (20D) | 1,933,055 |
| Open | 1.44 |
| Previous Close | 1.40 |
| Day's Range | 1.43 - 1.49 |
| 52-Week Range | 1.14 - 74.00 |
| Beta | 1.71 |
About BDRX
Biodexa Pharmaceuticals Plc, a drug delivery technology company, focuses on the bio-delivery and biodistribution of medicines in Belgium and internationally. The company is developing MTX110, a direct delivery treatment for diffuse intrinsic pontine glioma, medulloblastomas, and glioblastoma multiforme; MTD211, a long-acting formulation of brexpiprazole for the treatment of schizophrenia and adjunctive treatment of major depressive disorder; and ...
Industry Biotechnology
Sector Healthcare
IPO Date Dec 7, 2015
Employees 13
Stock Exchange NASDAQ
Ticker Symbol BDRX
Website https://www.biodexapharma.com
1 week ago
+12.74%
Biodexa Pharmaceuticals shares are trading higher ...
Unlock content with
Pro Subscription
1 month ago
+15.84%
Biodexa Pharmaceuticals shares are trading higher after the company announced it is on track to initiate Phase 3 trial in FAP next quarter.
